Phase II, Multicenter, Randomized Trial of Docetaxel Plus Prednisone With or Without Cediranib in Men With Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer

Oncologist - United States
doi 10.1634/theoncologist.2019-0331